EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Swiss TPH "Arpraziquantel, developed by the Pediatric Praziquantel Consortium, receives positive scientific opinion by the European Medicines Agency for the treatment of schistosomiasis in preschool-aged children. The Consortium's work to develop, register, and provide access to arpraziquantel is a tangible contribution to the elimination of schistosomiasis as a public health problem. As a member of the consortium, Swiss TPH conducted the clinical trials together with local partners."

• Swiss TPH
• Video